Shearman & Sterling advised the underwriters of Homology Medicines, Inc.’s initial public offering of 10,350,000 shares of common stock (including 1,350,000 shares purchased by the underwriters pursuant to their option to purchase additional shares) at a public offering price of $16 per share, resulting in gross proceeds to the company of approximately $165.6 million.  The shares began trading on The NASDAQ Global Select Market under the ticker symbol “FIXX” on March 28, 2018.  

BofA Merrill Lynch, Cowen and Evercore ISI acted as joint book-running managers for the offering and BTIG acted as the lead manager.  

Homology Medicines, Inc., is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease.  Homology’s proprietary platform is designed to utilize their human stem cell-derived virus vectors to precisely and efficiently deliver genetic medicines.  

The Shearman & Sterling team below was supported by Kathleen Mehary (New York–General Practice) and Jingjing Liang (New York–Compensation, Governance & ERISA).

The Team